| Title | Quantitative approaches to analyzing imatinib-treated chronic myeloid leukemia. | | Author(s) | Michor F | | Institution | Society of Fellows, Harvard University, Cambridge, MA 02138, USA; Dana Farber Cancer Institute, Boston, MA 02115, USA. | | Source | Trends Pharmacol Sci 2007 Apr 3. | | Abstract | Progress in understanding the genetic changes that drive tumorigenesis has enabled the development of molecularly targeted anticancer therapy. The first small molecule targeted to a specific protein was imatinib mesylate (Gleevec, STI571), which is used to treat chronic myeloid leukemia (CML). A recent article presents a computational model with which to study the treatment response in CML patients and investigates the effect that imatinib exerts on leukemic stem cells. Here, I discuss insights derived from this study and their implications for imatinib therapy against CML. | | Language | ENG | | Pub Type(s) | JOURNAL ARTICLE
| | PubMed ID | 17412430 |
|
